Hjem › KOL › Oklahoma › Oklahoma City
KOL kliniske forsøg i Oklahoma City, OK
5 studier for KOL søger deltagere på steder i og omkring Oklahoma City (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
RekruttererFase 3
- Research Site, Oklahoma City
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RekruttererFase 2
- Research Site, Oklahoma City
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RekruttererFase 3
- Research Site, Oklahoma City
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RekruttererFase 3
- Research Site, Oklahoma City
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RekruttererObservationsstudie
- Hightower Clinical, Oklahoma City
KOL forsøg i andre byer
- Philadelphia, PA23 studier
- Miami, FL18 studier
- Birmingham, AL17 studier
- Boston, MA17 studier
- Houston, TX15 studier
- Orlando, FL15 studier
- Baltimore, MD14 studier
- Chicago, IL14 studier
- Dallas, TX12 studier
- Pittsburgh, PA12 studier
- New York City, NY11 studier
- Ann Arbor, MI10 studier
Andre studier i Oklahoma City
- Ikke-småcellet lungecancer28 studier
- Ægstockræft28 studier
- Livmoderslimhindekræft25 studier
- Colorektal kræft22 studier
- Prostatakræft21 studier
- Lungecancer19 studier
- Brystkræft17 studier
- Metastatisk cancer15 studier
- Kræft (alle typer)14 studier
- Akut myeloid leukæmi14 studier
- Pladecellekræft i hoved og hals13 studier
- Bugspytkirtelkræft11 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.